The urology Group

Urology

Walter Rayford is an expert in the field of Urology. He researched medicine at University of Kansas School of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification". Dr. Walter Rayford has written publications. He has 48 publications published with PubMed. The lastest publication is: 'Management of hereditary pheochromocytoma in von Hippel-Lindau kindreds with partial adrenalectomy.' He is registered with Medicare.

Publications

---

• Characterization of germline copy number variation in high-risk African American families with prostate Cancer.
• Calcitonin is a Prostate epithelium-derived growth stimulatory peptide.
• Sarcoidosis presenting as bilateral Testicular masses.
• Practice patterns in the diagnosis and treatment of Erectile dysfunction among family practice physicians.
• Predictive value of preoperative tests in discriminating bilateral adRenal hyperplasia from an aldosterone-producing adRenal adenoma.
• Renal Cancer in families with hereditary renal Cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery.
• Management of hereditary pheochromocytoma in von Hippel-Lindau kindreds with partial adRenalectomy.
• Renal Cancer: preoperative evaluation with dual-phase three-dimensional MR angiography.
• Muscarinic cholinergic receptors promote growth of human prostate Cancer cells.
• Calcitonin stimulates growth of human prostate Cancer cells through receptor-mediated increase in cyclic adenosine 3',5'-monophosphates and cytoplasmic Ca2+ transients.
• A new polymorphic probe on chromosome 3p: lambda LIB39-63 (D3S616).
• A new polymorphic probe on chromosome 3p: lambda LIB27-77 (D3S603).
• A new polymorphic probe on chromosome 3p: lambda LIB45-86 (D3S633).
• A new polymorphic probe on chromosome 3p: lambda LIB27-98" (D3S1096).
• A new polymorphic probe on chromosome 3p:lambda LIB29-48(D3S624).
• A new polymorphic probe on chromosome 3p:lambda LIB25-55(D3S602).
• A new polymorphic probe on chromosome 3p:lambda LIB35-53(D3S731).
• A new polymorphic probe on chromosome 3p:lambda LIB11-95(D3S730).
• A new polymorphic probe on chromosome 3p:lambda LIB46-35''(D3S636).
• A new polymorphic probe on chromosome 3p:lambda LIB17-58(D3S598).
• A new polymorphic probe on chromosome 3p:lambda LIB46-95(D3S620).
• A new polymorphic probe on chromosome 3p:lambda LIB30-62''(D3S606).
• A new polymorphic probe on chromosome 3p:lambda LIB41-10(D3S618).
• Prostate specific antigen isoforms and human glandular kallikrein 2--which offers the best screening performance in a predominantly black population?
• Complexed PSA performance for prostate Cancer detection in an African-American population.
• cPSA and fPSA elimination in African-American men.
• Recruitment strategies and comparison of prostate Cancer-specific clinical data on African-American and Caucasian males with and without family history.
• Early detection of prostate Cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA ...
• Racial differences in trust and regular source of patient care and the implications for prostate Cancer screening use.
• Personality predicts prostate Cancer treatment decision-making difficulty and satisfaction.
• How to engage the Latino or African American patient with benign prostatic hyperplasia: crossing socioeconomic and cultural barriers.
• Gene expression profiling identifies clinically relevant subtypes of prostate Cancer.
• Racial differences in pathogenetic mechanisms, prevalence, and progression of benign prostatic hyperplasia.
• Managing the low-socioeconomic-status prostate Cancer patient.
• Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate Cancer.
• Similar age-specific PSA, complexed PSA, and percent cPSA levels among African-American and white men of southern Louisiana. Prostate-specific antigen.
• Induction of cell cycle arrest and apoptosis in human Prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1).
• A recombinant adenovirus expressing p7(Kip1) induces cell cycle arrest and apoptosis in human 786-0 Renal carcinoma cells.
• Knowledge, attitudes and beliefs of women about the importance of prostate Cancer screening.
• Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate Cancer and stromal c...
• Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate Cancer.
• The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management.
• TNF receptor 1 is involved in the induction of apoptosis by the cyclin dependent kinase inhibitor p27Kip1 in the prostate Cancer cell line PC-3.
• Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate Cancer and the implications for body-iron stores.
• Serum proteomic profiling can discriminate prostate Cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
• Establishment and characterization of a primary androgen-responsive African-American prostate Cancer cell line, E006AA.
• Serum ferritin levels and transferrin saturation in men with prostate Cancer.

Schools

---

• University Of MissouriKansas City School Of Medicine

• St Luke39s Hospital

• University Of Ks Med Center

Procedures Preformed

---

• AdRenalectomy
• AdRenalectomy With Robotic Assistance
• Cystometry
• Cystourethroscopy and Transurethral Resection of Bladder Neck
• View All

Conditions Treated

---

• Balanoposthitis
• Bladder Cancer
• Bladder Infection
• Bladder Stones
• View All

Doctors Specialties

---

• Urology

Accepted Insurances

---

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• University of Kansas School of Medicine

Hospital

---

• University of Tennessee Medical Center

Drug Facts

---

NPI NUMBER		1821103151
NPPES Provider LastName		RAYFORD
NPPES Provider FirstName		WALTER
NPPES Provider ZIPCode		381202112
NPPES Provider State		TN
Specialty Description		Urology
Total Claim Count		3633.0
Distinct Opioid Count		2.0
Opioid Claim Count		417.0
Percent Opioid Claims		11.48

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1821103151
Last Name Of The Provider	RAYFORD
First Name Of The Provider	WALTER
View All

Similar Doctors

---

	Dr. William V. Shappley III, MD This Doctor is OpenDoctor Recommended.
	Dr. William V. Shappley Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Nimmagadda V. Raghavaiah, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Mark D. Greenberger, MD This Doctor is OpenDoctor Recommended.
	Dr. Dejo Viprakasit, MD This Doctor is OpenDoctor Recommended.
	Dr. David Gubin, MD This Doctor is OpenDoctor Recommended.
	Dr. Ricky A. Smith, MD This Doctor is OpenDoctor Recommended.
	Dr. John M. Gregory, MD
	Dr. Bayo D. Tojuola, MD
	Dr. Joseph J. Welser, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog